Hospitals and investigators
Build prospective evidence and study what molecular change may mean for different patients and settings.
Partnerships
No one builds a new standard alone
so the next chapter depends on working together
VitaGuard begins with a functioning technology and commercial operating experience. Its wider future will depend on hospitals, laboratories, researchers, biopharma and regional leaders working together.
Shared ambition
Different expertise can create
one clearer view over time
Fidelion brings assigned VitaGuard rights, an established workflow and implementation support for longitudinal molecular testing.
Our partners bring the clinical insight, laboratory capability, research questions and local knowledge needed to turn a promising technology into trusted use.
Reference and health-system labs
Establish the workflow reproducibly and bring high-quality monitoring closer to patients.
Drug-development partners
Explore molecular response, recurrence and biomarkers across the course of treatment.
Commercial and market partners
Build responsible access around local evidence, quality, regulation and care pathways.
A first regional pathway
Southeast Asia is where the next chapter takes shape
BioNexus Gene Lab Corp. holds exclusive Southeast Asian rights to VitaGuard under its agreement with Fidelion. Regional activity remains subject to validation and applicable requirements.